Interleukin-1 beta downstream signaling pathway (IL-1β pathway)

The Interleukin-1 beta (IL-1β) downstream signaling pathway is a fundamental component of the innate immune system, responsible for orchestrating inflammatory responses (Weber et al., 2010, Sci. Signal. [1]). The process is initiated when IL-1β binds to the Interleukin-1 receptor type 1 (IL-1R1), leading to the recruitment of the IL-1 receptor accessory protein (IL-1RAcP) (Wang et al., 2010, Nature Immunology [2]). This assembly triggers the recruitment of the adapter protein MyD88 and the Interleukin-1 receptor-associated kinase (IRAK) complex, specifically IRAK1, IRAK2, and IRAK4 (Li et al., 2002, PNAS [3]). Subsequent activation of the IκB kinase (IKK) complex and mitogen-activated protein kinases (MAPKs) leads to the nuclear translocation of transcription factors like NF-κB and AP-1, which induce the expression of pro-inflammatory genes (Dinarello, 2009, Annu. Rev. Immunol. [4]). Chronic overactivation of this pathway is implicated in diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes (CAPS), and cardiovascular disease (Ridker et al., 2017, NEJM [5]). Therapeutic strategies include the use of IL-1 receptor antagonists like Anakinra and monoclonal antibodies like Canakinumab to neutralize the pathway's activity (FDA, 2020 [6]). Additionally, small molecule inhibitors targeting downstream components like IRAK4 are currently under clinical investigation for various inflammatory conditions (Kuzmich et al., 2021, J. Med. Chem. [7]).

Other names

IL-1 signaling cascadeIL-1R1 signaling pathwayInterleukin-1 receptor signalingIL-1-mediated signaling

Drugs targeting this pathway function by blocking the IL-1R1 receptor, neutralizing the IL-1β ligand, or inhibiting downstream kinases like IRAK4 to prevent pro-inflammatory gene expression (Dinarello, 2011, Blood [7]).